Stochastic Processes and the Dirac Equation with External Fields

The equation describing the stochastic motion of a classical particle in 1+1-dimensional space-time is connected to the Dirac equation with external gauge fields. The effects of assigning different turning probabilities to the forward and the backward moving particles in time are discussed.Comment: 9 pages, 1 figure, scalar parts eliminate

Comprehensive understanding of cathodic and anodic polarization effects on stability of nanoscale oxygen electrode for reversible solid oxide cells

Whereas solid oxide cells (SOCs), which perform dual functions of power generation (fuel-cell mode) and energy storage (electrolysis mode) with high efficiency at high temperatures, are considered a potent candidate for future energy management systems, it is yet far from their practical use due to the fact that the stable long-term operations have not been achieved. Particularly, degradations of oxygen-electrode in the both electrolysis and fuel-cell operations are considered as the most imminent issues that should be overcome. Unfortunately, even the origins and mechanisms of degradation in the oxygen-electrode have not been clearly established due to the difficulties in precise assessments of microstructural/compositional changes of porous electrode, which is a typical form in actual solid oxide cells, and due to the diversities in operating conditions, electrode structure and material, fabrication history, and so on. We simultaneously investigated the degradation phenomena in electrolysis and fuel-cell operations for 540h using identical two half cells composed of a geometrically well-defined, nanoscale La0.6Sr0.4Co0.2Fe0.8O3-δ (LSCF) dense film with a thickness of ~ 70 nm on Ce0.9Gd0.1O2-δ electrolyte. Owing to the benefit of well-defined geometry of LSCF thin film, the microstructural/compositional changes in LSCF films were successfully analyzed in nanoscale, and the correlation between the components of electrochemical impedance and the major origins resulting in degradations was clarified. Furthermore, we suggest the most probable degradation mechanisms, and importantly, it is newly suggested that kinetic demixing/decomposition of LSCF, which is not readily observable in the typical porous-structured electrode, are highly probable to affect the both fuel-cell and electrolysis long-term degradations

Requirement for Pak3 in Rac1-induced organization of actin and myosin during Drosophila larval wound healing

AbstractRho-family small GTPases regulate epithelial cell sheet migration by organizing actin and myosin during wound healing. Here, we report that Pak3, but not Pak1, is a downstream target protein for Rac1 in wound closure of the Drosophila larval epidermis. Pak3-deficient larvae failed to close a wound hole and this defect was not rescued by Pak1 expression, indicating differential functions of the two proteins. Pak3 localized to the wound margin, which selectively required Rac1. Pak3-deficient larvae showed severe defects in actin-myosin organization at the wound margin and in submarginal cells, which was reminiscent of the phenotypes of Rac1-deficient larvae. These results suggest that Pak3 specifically mediates Rac1 signaling in organizing actin and myosin during Drosophila epidermal wound healing

Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study

<p>Abstract</p> <p>Background</p> <p>The objective of this trial was to compare the blood-pressure lowering efficacy of amlodipine/losartan combination with amlodipine monotherapy after 6 weeks of treatment in Korean patients with stage 2 hypertension.</p> <p>Results</p> <p>In this multi-center, double-blind, randomized study, adult patients (n = 148) with stage 2 hypertension were randomized to amlodipine 5 mg/losartan 50 mg or amlodipine 5 mg. After 2 weeks, patients with systolic blood pressure (SBP) > 140 mmHg were titrated to amlodipine 10 mg/losartan 50 mg or amlodipine 10 mg. After 4 weeks of titration, hydrochlorothiazide 12.5 mg could be optionally added to both groups. The change from baseline in SBP was assessed after 6 weeks. The responder rate (defined as achieving SBP < 140 mmHg or DBP < 90 mmHg) was also assessed at 2, 6 and 8 weeks as secondary endpoints. Safety and tolerability were assessed through adverse event monitoring and laboratory testing. Baseline demographics and clinical characteristics were generally similar between treatment groups. Least-square mean reduction in SBP at 6 weeks (primary endpoint) was significantly greater in the combination group (36.5 mmHg vs. 31.6 mmHg; p = 0.0117). The responder rate in SBP (secondary endpoints) was significantly higher in the combination group at 2 weeks (52.1% vs. 33.3%; p = 0.0213) but not at 6 weeks (p = 0.0550) or 8 weeks (p = 0.0592). There was no significant difference between groups in the incidence of adverse events.</p> <p>Conclusion</p> <p>These results demonstrate that combination amlodipine/losartan therapy provides an effective and generally well-tolerated first line therapy for reducing blood pressure in stage 2 hypertensive patients.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01127217">NCT01127217</a></p